Abeona Therapeutics (ABEO) Long-Term Debt Issuances (2020 - 2024)
Abeona Therapeutics' (ABEO) quarterly Long-Term Debt Issuances came in at $20.0 million in Q1 2024, up 47719.05% quarter-over-quarter from -$42000.0 in Q2 2020.
Abeona Therapeutics (ABEO) Long-Term Debt Issuances (2020 - 2024) Analysis & Trends
Abeona Therapeutics' Long-Term Debt Issuances history runs 2 years deep, the most recent figure standing at $20.0 million for Q1 2024.
- On a quarterly basis, Long-Term Debt Issuances changed N/A year-over-year to $20.0 million in Q1 2024; TTM through Dec 2024 was $20.0 million, a N/A change from a year earlier, with the FY2024 full-year figure at $20.0 million, changed N/A from the prior year.
- Long-Term Debt Issuances advanced to $20.0 million in Q1 2024 per ABEO's latest filing, from -$42000.0 in the prior quarter.
- Across five years, Long-Term Debt Issuances topped out at $20.0 million in Q1 2024 and bottomed at -$42000.0 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Abeona Therapeutics | 107.85 Mn | -60.42 Mn | 6.02 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 20.00 Mn |
| Mar 31, 2024 | 20.00 Mn |
| Jun 30, 2020 | -42,000.00 |
| Jun 30, 2020 | -42,000.00 |